Information for MND Association members
Dexpramipexole (formally known as KNS-760704) is a newly synthesised drug created by Knopp Neuroscience Inc. Although it is not currently known how this drug works in the body, laboratory studies have demonstrated that this drug has neuroprotective properties. A phase II trial of KNS-760704, completed in 2009, found that the drug was safe and well tolerated by people with MND for up to 9 months. The trial results also showed trends suggesting the drug's potential for reducing the rate of decline in patients' functional capability, although the relatively small numbers of people involved in the study means that these findings cannot be relied upon.
During 2011 recruitment commenced for a phase three study of the drug dexpramipexole at 61 study locations in the United States, Europe and Australia. Recruitment has now closed. The purpose of this study is to determine whether dexpramipexole (150 mg twice daily) is safe and effective in the treatment of ALS/MND.
Advance is the newsletter of the MND Research Institute of Australia - the research arm of MND Australia.